{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:23:09Z","timestamp":1793316189029,"version":"4.5.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>To characterize the pediatric super-refractory status epilepticus population by describing treatment variability in super-refractory status epilepticus patients and comparing relevant clinical characteristics, including outcomes, between super-refractory status epilepticus, and nonsuper-refractory status epilepticus patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective cohort study with prospectively collected data between June 2011 and January 2019.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Seventeen academic hospitals in the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>We included patients 1 month to 21 years old presenting with convulsive refractory status epilepticus. We defined super-refractory status epilepticus as continuous or intermittent seizures lasting greater than or equal to 24 hours following initiation of continuous infusion and divided the cohort into super-refractory status epilepticus and nonsuper-refractory status epilepticus groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>We identified 281 patients (157 males) with a median age of 4.1 years (1.3\u20139.5 yr), including 31 super-refractory status epilepticus patients. Compared with nonsuper-refractory status epilepticus group, super-refractory status epilepticus patients had delayed initiation of first nonbenzodiazepine-antiseizure medication (149\u2009min [55\u2013491.5 min] vs 62\u2009min [33.3\u2013120.8 min]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.030) and of continuous infusion (495\u2009min [177.5\u20131,255 min] vs 150\u2009min [90\u2013318.5 min]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.003); prolonged seizure duration (120\u2009hr [58\u2013368 hr] vs 3\u2009hr [1.4\u20135.9 hr]; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001) and length of ICU stay (17 d [9.5\u201340 d] vs [1.8\u20138.8 d]; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001); more medical complications (18\/31 [58.1%] vs 55\/250 [22.2%] patients; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001); lower return to baseline function (7\/31 [22.6%] vs 182\/250 [73.4%] patients; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001); and higher mortality (4\/31 [12.9%] vs 5\/250 [2%]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.010). Within the super-refractory status epilepticus group, status epilepticus resolution was attained with a single continuous infusion in 15 of 31 patients (48.4%), two in 10 of 31 (32.3%), and three or more in six of 31 (19.4%). Most super-refractory status epilepticus patients (30\/31, 96.8%) received midazolam as first choice. About 17 of 31 patients (54.8%) received additional treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Super-refractory status epilepticus patients had delayed initiation of nonbenzodiazepine antiseizure medication treatment, higher number of medical complications and mortality, and lower return to neurologic baseline than nonsuper-refractory status epilepticus patients, although these associations were not adjusted for potential confounders. Treatment approaches following the first continuous infusion were heterogeneous, reflecting limited information to guide clinical decision-making in super-refractory status epilepticus.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pcc.0000000000002786","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:01:05Z","timestamp":1623628865000},"page":"e613-e625","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study"],"prefix":"10.1097","volume":"22","author":[{"given":"Alejandra","family":"Vasquez","sequence":"first","affiliation":[{"name":"Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA."},{"name":"Division of Child and Adolescent Neurology, Department of Neurology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Farias-Moeller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Pediatric Neurology, Children\u2019s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"S\u00e1nchez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA."},{"name":"Department of Child Neurology, Hospital Sant Joan de D\u00e9u, Universidad de Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Abend","sequence":"additional","affiliation":[{"name":"Division of Neurology, The Children\u2019s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Amengual-Gual","sequence":"additional","affiliation":[{"name":"Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA."},{"name":"Pediatric Neurology Unit, Department of Pediatrics, Hospital Universitari Son Espases, Universitat de les Illes Balears, Palma, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Anderson","sequence":"additional","affiliation":[{"name":"Section of Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Arya","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Brenton","sequence":"additional","affiliation":[{"name":"Department of Neurology and Pediatrics, University of Virginia Health System, Charlottesville, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Center for Neuroscience, Children\u2019s National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chapman","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Neurology, Children\u2019s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justice","family":"Clark","sequence":"additional","affiliation":[{"name":"Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Gaillard","sequence":"additional","affiliation":[{"name":"Center for Neuroscience, Children\u2019s National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Glauser","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Ruth D. & Ken M. Davee Pediatric Neurocritical Care Program, Northwestern University Feinberg School of Medicine, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard P.","family":"Goodkin","sequence":"additional","affiliation":[{"name":"Department of Neurology and Pediatrics, University of Virginia Health System, Charlottesville, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejean M.","family":"Guerriero","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Washington University Medical Center, Washington University School of Medicine, Saint Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Lai","sequence":"additional","affiliation":[{"name":"Section of Pediatric Critical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffani L.","family":"McDonough","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Neurology, Columbia University Medical Center, Columbia University, New York, NY."},{"name":"Division of Pediatric Neurology, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad A.","family":"Mikati","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Duke University Medical Center, Duke University, Durham, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Pediatric Neurology, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Novotny","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Pediatric Neurology, University of Washington, Seattle, WA."},{"name":"Center for Integrative Brain Research, Seattle Children\u2019s Research Institute, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Ostendorf","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nationwide Children\u2019s Hospital, The Ohio State University. Columbus, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Payne","sequence":"additional","affiliation":[{"name":"Division of Child and Adolescent Neurology, Department of Neurology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Peariso","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Piantino","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division Pediatric Neurology, Neuro-Critical Care Program, Oregon Health and Science University, Portland, OR."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Riviello","sequence":"additional","affiliation":[{"name":"Section of Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan T.","family":"Sands","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Neurology, Columbia University Medical Center, Columbia University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Sannagowdara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Pediatric Neurology, Children\u2019s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Tasker","sequence":"additional","affiliation":[{"name":"Division of Critical Care, Departments of Neurology, Anesthesiology, Perioperative and Pain Medicine, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Tchapyjnikov","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Duke University Medical Center, Duke University, Durham, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Topjian","sequence":"additional","affiliation":[{"name":"Critical Care and Pediatrics, The Children\u2019s Hospital of Philadelphia, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Wainwright","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Pediatric Neurology, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus","family":"Wilfong","sequence":"additional","affiliation":[{"name":"Department of Child Health, University of Arizona College of Medicine and Barrow\u2019s Neurological Institute at Phoenix Children\u2019s Hospital, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korwyn","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Child Health, University of Arizona College of Medicine and Barrow\u2019s Neurological Institute at Phoenix Children\u2019s Hospital, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Loddenkemper","sequence":"additional","affiliation":[{"name":"Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Pediatric Status Epilepticus Research Group (pSERG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ejpn.2013.05.001","article-title":"Ketogenic diet in 3 cases of childhood refractory status epilepticus.","volume":"17","author":"Sort","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus.","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit Care"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/brain\/aws091","article-title":"The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy.","volume":"135","author":"Ferlisi","year":"2012","journal-title":"Brain"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11910-014-0452-x","article-title":"Refractory and super-refractory status epilepticus\u2013an update.","volume":"14","author":"Hocker","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2013report of the ILAE task force on classification of status epilepticus.","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ane.12605","article-title":"Refractory and super-refractory status epilepticus in adults: A 9-year cohort study.","volume":"135","author":"Delaj","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ane.12336","article-title":"Super-refractory status epilepticus in West China.","volume":"132","author":"Tian","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2015.04.065","article-title":"Incidence and mortality of super-refractory status epilepticus in adults.","volume":"49","author":"Kantanen","year":"2015","journal-title":"Epilepsy Behav"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s00134-017-4837-6","article-title":"Super-refractory status epilepticus: Epidemiology, early predictors, and outcomes.","volume":"43","author":"Chateauneuf","year":"2017","journal-title":"Intensive Care Med"},{"issue":"Suppl 8","key":"R10-20250502","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1528-1167.2011.03238.x","article-title":"Super-refractory status epilepticus: An approach to therapy in this difficult clinical situation.","volume":"52","author":"Shorvon","year":"2011","journal-title":"Epilepsia"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.eplepsyres.2014.08.010","article-title":"Determinants and predictors of outcome in super refractory status epilepticus\u2013a developing country perspective.","volume":"108","author":"Jayalakshmi","year":"2014","journal-title":"Epilepsy Res"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1093\/brain\/awr215","article-title":"The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol.","volume":"134","author":"Shorvon","year":"2011","journal-title":"Brain"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11910-015-0589-2","article-title":"Treatment of super-refractory status epilepticus.","volume":"15","author":"Bayrlee","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Suppl 2","key":"R14-20250502","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/epi.14496","article-title":"Etiologies and characteristics of refractory status epilepticus cases in different areas of the world: Results from a global audit.","volume":"59","author":"Ferlisi","year":"2018","journal-title":"Epilepsia"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/jamaneurol.2013.578","article-title":"Predictors of outcome in refractory status epilepticus.","volume":"70","author":"Hocker","year":"2013","journal-title":"JAMA Neurol"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/epi.16382","article-title":"Treatment of refractory and super-refractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature.","volume":"60","author":"Fechner","year":"2019","journal-title":"Epilepsia"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/epi.12895","article-title":"ICD coding for epilepsy: Past, present, and future\u2013a report by the International League Against Epilepsy Task Force on ICD codes in epilepsy.","volume":"56","author":"Jette","year":"2015","journal-title":"Epilepsia"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/epi.13837","article-title":"Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany.","volume":"58","author":"Strzelczyk","year":"2017","journal-title":"Epilepsia"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"e20172151","DOI":"10.1542\/peds.2017-2151","article-title":"Age limit of pediatrics.","volume":"140","author":"Hardin","year":"2017","journal-title":"Pediatrics"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12887-019-1508-5","article-title":"Etiology of neonatal seizures and maintenance therapy use: A 10-year retrospective study at Toulouse Children\u2019s hospital.","volume":"19","author":"Baudou","year":"2019","journal-title":"BMC Pediatr"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.siny.2018.02.002","article-title":"Acute symptomatic seizures in term neonates: Etiologies and treatments.","volume":"23","author":"Soul","year":"2018","journal-title":"Semin Fetal Neonatal Med"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.siny.2013.05.008","article-title":"Epidemiology and aetiology of neonatal seizures.","volume":"18","author":"Vasudevan","year":"2013","journal-title":"Semin Fetal Neonatal Med"},{"key":"R23-20250502","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jclinepi.2014.03.012","article-title":"False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies.","volume":"67","author":"Glickman","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"R24-20250502","article-title":"R: A Language and Environment for Statistical Computing. Version 3.4.1 (2017-06-30).","year":"2017","journal-title":"R Foundation for Statistical Computing, Vienna, Austria"},{"key":"R30-20250502","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1212\/WNL.0000000000001673","article-title":"Time from convulsive status epilepticus onset to anticonvulsant administration in children.","volume":"84","author":"S\u00e1nchez Fern\u00e1ndez","year":"2015","journal-title":"Neurology"},{"key":"R31-20250502","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/01.wnl.0000180959.31355.92","article-title":"Treatment delay and the risk of prolonged status epilepticus.","volume":"65","author":"Eriksson","year":"2005","journal-title":"Neurology"},{"key":"R32-20250502","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0887-8994(95)00044-G","article-title":"Effect of prehospital treatment on the outcome of status epilepticus in children.","volume":"12","author":"Alldredge","year":"1995","journal-title":"Pediatr Neurol"},{"key":"R33-20250502","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/j.1528-1167.2008.01669.x","article-title":"How do seizures stop?","volume":"49","author":"Lado","year":"2008","journal-title":"Epilepsia"},{"key":"R34-20250502","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneur.59.2.205","article-title":"Refractory status epilepticus: Frequency, risk factors, and impact on outcome.","volume":"59","author":"Mayer","year":"2002","journal-title":"Arch Neurol"},{"key":"R35-20250502","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1474-4422(08)70141-8","article-title":"Treatment of community-onset, childhood convulsive status epilepticus: A prospective, population-based study.","volume":"7","author":"Chin","year":"2008","journal-title":"Lancet Neurol"},{"key":"R36-20250502","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ejpn.2015.05.007","article-title":"Etiology, clinical course and response to the treatment of status epilepticus in children: A 16-year single-center experience based on 602 episodes of status epilepticus.","volume":"19","author":"Kravljanac","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"R37-20250502","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.neurol.2009.12.009","article-title":"[Use of midazolam for refractory status epilepticus in children].","volume":"166","author":"Lampin","year":"2010","journal-title":"Rev Neurol (Paris)"},{"key":"R38-20250502","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/PCC.0000000000000173","article-title":"Intensive care treatment of uncontrolled status epilepticus in children: Systematic literature search of midazolam and anesthetic therapies*.","volume":"15","author":"Wilkes","year":"2014","journal-title":"Pediatr Crit Care Med"},{"key":"R39-20250502","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1046\/j.1528-1157.2001.0420081031.x","article-title":"Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus.","volume":"42","author":"Logroscino","year":"2001","journal-title":"Epilepsia"},{"key":"R40-20250502","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/archneurol.2009.273","article-title":"Functional and cognitive outcome in prolonged refractory status epilepticus.","volume":"66","author":"Cooper","year":"2009","journal-title":"Arch Neurol"},{"key":"R41-20250502","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12028-013-9935-x","article-title":"The epidemiology of status epilepticus in the United States.","volume":"20","author":"Dham","year":"2014","journal-title":"Neurocrit Care"},{"key":"R42-20250502","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/13696998.2016.1223680","article-title":"Burden of illness for super-refractory status epilepticus patients.","volume":"20","author":"Beg","year":"2017","journal-title":"J Med Econ"},{"key":"R43-20250502","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.seizure.2017.09.003","article-title":"Factors associated with occurrence and outcome of super-refractory status epilepticus.","volume":"52","author":"Mad\u017ear","year":"2017","journal-title":"Seizure"},{"key":"R44-20250502","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yebeh.2018.06.029","article-title":"The etiology and prognosis of super-refractory convulsive status epilepticus in children.","volume":"86","author":"Lu","year":"2018","journal-title":"Epilepsy Behav"},{"key":"R45-20250502","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.braindev.2018.11.011","article-title":"Treatment options in pediatric super-refractory status epilepticus.","volume":"41","author":"Arayakarnkul","year":"2019","journal-title":"Brain Dev"},{"key":"R46-20250502","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ccc.2012.11.007","article-title":"Pediatric intensive care treatment of uncontrolled status epilepticus.","volume":"29","author":"Wilkes","year":"2013","journal-title":"Crit Care Clin"},{"key":"R47-20250502","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/PCC.0000000000000900","article-title":"Refractory status epilepticus in children: Intention to treat with continuous infusions of midazolam and pentobarbital.","volume":"17","author":"Tasker","year":"2016","journal-title":"Pediatr Crit Care Med"},{"key":"R48-20250502","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0883073817698629","article-title":"Increasing ketamine use for refractory status epilepticus in US pediatric hospitals.","volume":"32","author":"Keros","year":"2017","journal-title":"J Child Neurol"},{"key":"R49-20250502","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1517\/14656566.2016.1127354","article-title":"Pharmacologic treatment of status epilepticus.","volume":"17","author":"Trinka","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"R50-20250502","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/epi.14676","article-title":"Starting ketamine for neuroprotection earlier than its current use as an anesthetic\/antiepileptic drug late in refractory status epilepticus.","volume":"60","author":"Fujikawa","year":"2019","journal-title":"Epilepsia"},{"key":"R51-20250502","doi-asserted-by":"crossref","first-page":"e011565","DOI":"10.1136\/bmjopen-2016-011565","article-title":"Efficacy of ketamine in refractory convulsive status epilepticus in children: A protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01).","volume":"6","author":"Rosati","year":"2016","journal-title":"BMJ Open"},{"key":"R52-20250502","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.112.4.1002","article-title":"The FDA warning against prolonged sedation with propofol in children remains warranted.","volume":"112","author":"Felmet","year":"2003","journal-title":"Pediatrics"},{"key":"R53-20250502","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40263-015-0259-6","article-title":"Propofol: A review of its role in pediatric anesthesia and sedation.","volume":"29","author":"Chidambaran","year":"2015","journal-title":"CNS Drugs"},{"key":"R54-20250502","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.bja.2018.12.025","article-title":"Propofol infusion syndrome: A structured literature review and analysis of published case reports.","volume":"122","author":"Hemphill","year":"2019","journal-title":"Br J Anaesth"},{"key":"R55-20250502","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s13054-015-1112-5","article-title":"Propofol infusion syndrome: A structured review of experimental studies and 153 published case reports.","volume":"19","author":"Kraj\u010dov\u00e1","year":"2015","journal-title":"Crit Care"},{"key":"R56-20250502","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1592\/phco.27.4.519","article-title":"Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients.","volume":"27","author":"Taylor","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R57-20250502","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/01616412.2016.1206164","article-title":"Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients.","volume":"38","author":"Van Matre","year":"2016","journal-title":"Neurol Res"},{"key":"R58-20250502","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1212\/WNL.54.11.2188-a","article-title":"Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus.","volume":"54","author":"Uberall","year":"2000","journal-title":"Neurology"},{"key":"R59-20250502","doi-asserted-by":"crossref","first-page":"106296","DOI":"10.1016\/j.yebeh.2019.04.049","article-title":"Lessons from the Established Status Epilepticus Treatment Trial.","volume":"101","author":"Cock","year":"2019","journal-title":"Epilepsy Behav"},{"key":"R61-20250502","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.yebeh.2009.10.020","article-title":"Intravenous immunoglobulin therapy in intractable childhood epilepsy: Open-label study and review of the literature.","volume":"17","author":"Mikati","year":"2010","journal-title":"Epilepsy Behav"},{"key":"R62-20250502","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0887-8994(02)00513-1","article-title":"Prednisone therapy in pediatric epilepsy.","volume":"28","author":"Sinclair","year":"2003","journal-title":"Pediatr Neurol"},{"key":"R63-20250502","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1528-1157.1990.tb05518.x","article-title":"Landau-Kleffner syndrome: A pharmacologic study of five cases.","volume":"31","author":"Marescaux","year":"1990","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"R64-20250502","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s100720200013","article-title":"The use of immunoglobulins in the treatment of human epilepsy.","volume":"23","author":"Villani","year":"2002","journal-title":"Neurol Sci"},{"key":"R65-20250502","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy.","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"R66-20250502","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11940-013-0252-7","article-title":"Autoimmune status epilepticus.","volume":"15","author":"Lopinto-Khoury","year":"2013","journal-title":"Curr Treat Options Neurol"},{"key":"R67-20250502","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2013.07.020","article-title":"The ketogenic diet for the treatment of pediatric status epilepticus.","volume":"50","author":"O\u2019Connor","year":"2014","journal-title":"Pediatr Neurol"},{"key":"R68-20250502","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1111\/j.1528-1167.2010.02703.x","article-title":"Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES).","volume":"51","author":"Nabbout","year":"2010","journal-title":"Epilepsia"},{"key":"R69-20250502","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/0883073813516192","article-title":"The ketogenic diet as broad-spectrum treatment for super-refractory pediatric status epilepticus: Challenges in implementation in the pediatric and neonatal intensive care units.","volume":"30","author":"Cobo","year":"2015","journal-title":"J Child Neurol"},{"key":"R70-20250502","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.seizure.2016.07.006","article-title":"Ketogenic diet treatment for pediatric super-refractory status epilepticus.","volume":"41","author":"Appavu","year":"2016","journal-title":"Seizure"},{"key":"R71-20250502","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12028-016-0312-4","article-title":"A practical approach to ketogenic diet in the pediatric intensive care unit for super-refractory status epilepticus.","volume":"26","author":"Farias-Moeller","year":"2017","journal-title":"Neurocrit Care"},{"key":"R72-20250502","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.braindev.2018.12.007","article-title":"The ketogenic diet for super-refractory status epilepticus patients in intensive care units.","volume":"41","author":"Park","year":"2019","journal-title":"Brain Dev"},{"key":"R73-20250502","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fneur.2019.00423","article-title":"Ketogenic diet as a treatment for super-refractory status epilepticus in febrile infection-related epilepsy syndrome.","volume":"10","author":"Peng","year":"2019","journal-title":"Front Neurol"},{"key":"R74-20250502","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1212\/WNL.0b013e318278b685","article-title":"Efficacy and safety of ketamine in refractory status epilepticus in children.","volume":"79","author":"Rosati","year":"2012","journal-title":"Neurology"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000002786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:33:59Z","timestamp":1746207239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000002786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000002786","relation":{},"ISSN":["1529-7535"],"issn-type":[{"value":"1529-7535","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,14]]}}}